mRNA COVID Sales Drop to $5.8 Billion: The Urgency Behind the Pipeline Shift
Pfizer’s Q1 2025 disclosure showed Comirnaty revenue at just $2.2 billion for the trailing twelve months, down more than 80% from peak pandemic levels. Moderna’s 2025 guidance for Spikevax revenue is even lower, at $1.6 billion. The COVID gold rush is spent. This leaves the mRNA vaccine platforms with a stark challenge: after pouring $15 billion into manufacturing infrastructure, R&D, and fixed costs, they need new infectious disease targets to justify it all. Pfizer, Moderna, and several smaller mRNA players are now hunting for a viable second act. But the economics and science are, frankly, not cooperating as neatly as the COVID story did.
This new direction is driven by necessity rather than inspiration. Without COVID’s outsized windfalls, mRNA vaccine players face classic pharma pressure: either recoup that R&D spend with new products or risk pipeline stagnation. Sell-side projections now put the total non-COVID mRNA vaccine market at $7-10 billion through 2028, almost all of it dependent on RSV, flu, and CMV programs. The real question: Can these new candidates generate the kind of revenue that made COVID a once-in-a-generation event for the sector? The data is mixed.
For a snapshot of how traditional vaccine pricing and payer reimbursement compare to those pandemic COVID figures, see RxInfo.ai.
RSV, Influenza, and a New Wave of Infectious Disease Programs
First up is RSV, the initial stress test for post-pandemic mRNA. In May 2024, Moderna’s mRNA-1345 RSV vaccine secured FDA approval, following closely behind GSK and Pfizer’s more traditional biologic RSV vaccines. Moderna’s label targets adults 60 and older. The CDC’s ACIP estimated a maximum pool of 30 million eligible adults per year, nothing like the blockbuster COVID campaigns. At $190 per dose, Moderna’s RSV sales could top out around $1.3 billion annually if it snags a quarter of the three-player market. Considerably less oxygen in the room than COVID ever enjoyed.
The landscape for adult influenza vaccines is even more congested. In 2023, Moderna’s phase 3 flu candidate, mRNA-1010, failed on its primary endpoints for two of the four dominant strains, forcing a reformulation. Pfizer’s mRNA flu push lags by a year, while Sanofi and CSL (Seqirus) already own the differentiated, adjuvanted, and cell-based segments. Payers aren’t waiting with open wallets. Commercial plans and Medicare Part D are making clear they’ll only treat new mRNA flu vaccines as true improvements if they reduce hospitalizations or severe disease, not just incremental tweaks.
Then there’s cytomegalovirus (CMV). Here, Moderna’s mRNA-1647 is the leading phase 3 program, going after a first-ever vaccine for a tricky infection with no current prophylactic options. Sell-side scenarios model $2 billion in peak annual sales if all goes perfectly, but that may be generous. The target population is relatively small and slow to mobilize, so nobody really knows the true market size yet.
A string of preclinical mRNA projects is also targeting infections like Epstein-Barr, Zika, and Dengue. But don’t expect meaningful revenues before 2027, if then. Most of these programs rely on government or philanthropic dollars, not commercial insurance markets. The industry is clearly hoping early IP wins will pay off, but for now, there’s little evidence these bets will deliver broad returns. For the payer and public health funding context, check RxPBM.ai.
Where the Money Flows, and How Much Is Left
Since 2021, the scale of capital outflows has been hard to ignore. In 2024, Moderna reported $4.5 billion in R&D spend, two-thirds funneled into infectious disease. Pfizer’s vaccine investment, once inflated by $9 billion COVID receipts, now faces cost-cutting and pipeline triage. Investors, especially the activist crowd, are demanding visible commercial payoff, not just scientific ambition.
The partnership landscape is reflecting this new mood. Gone are the headline biobucks deals; in their place, smaller, milestone-tied collaborations. BioNTech’s 2024 agreement with CEPI for rapid response mRNA vaccines came with only $35 million up front, with real payouts dependent on deployment during actual outbreaks. GSK, who mostly skipped the mRNA COVID race, has built a pipeline through acquisitions and internal programs, but the company isn’t racing to match the scale of Pfizer or Moderna’s spend. (Honestly, a wise move in this market.)
What the sector really lacks now is the type of government guarantee that underpinned the COVID boom. US BARDA and Europe’s HERA continue funding pandemic prep, but their advance purchase orders are a shadow of what they were. No billion-dollar contracts, no comfortable overbuilding of capacity. So mRNA vaccine developers are now living with the same uncertainty as the rest of pharma: clinical risk, payer pushback, unpredictable demand. The impact is plain to see, Moderna’s stock now trades below 4x expected vaccine sales, a far cry from the 30x multiples of the COVID surge.
Scientific Barriers: Where mRNA Hits Immunological Roadblocks
Here’s the blunt truth: mRNA isn’t the universal fix pharma once hoped for. COVID was a rare case, in one spike protein, an unexposed population, and explosive spread. RSV and flu, by comparison, pose thorny challenges. Both feature constant antigenic drift and tangled immune histories among adults. Speed is where mRNA shines: you can design and manufacture a vaccine in a matter of months. But that’s only half the solution. Take flu, for example. Clinical efficacy across strains has been inconsistent, and there’s still no consensus on durability of protection. Lingering question marks.
With targets like CMV or EBV, the technology faces new layers of difficulty. CMV vaccines require a cocktail approach, with multiple glycoprotein targets per dose. Moderna’s CMV candidate combines six different mRNA strands. Early data on immune response look promising, even encouraging, but scaling up manufacturing and keeping COGS low is a puzzle that hasn’t actually been solved. Not outside of small batch runs, anyway.
There’s still some real hope for mRNA in rapid pandemic response. Agencies like CEPI and BARDA will likely keep stockpiling mRNA capabilities for future emergencies. But the grand vision of mRNA as a plug-and-play solution for all infectious diseases is running aground on tough immune biology and payer realities.
For clinical trial data and upcoming mRNA milestones, check ClinicalRx.ai.
Conclusion: The Post-COVID mRNA Economics Landscape
The landscape for mRNA vaccine platforms changed radically by 2025. Those wild COVID windfalls are history, and new infectious disease arenas come with much less straightforward scientific and commercial paths. Now, investors want actual pipeline productivity, not just the option of pandemic heroics. RSV, flu, and CMV look like the next real commercial opportunities, but together they might deliver just $5-7 billion in annual sales by 2028, a far cry from COVID’s $60 billion run. The trajectory will likely hinge on how much payers and governments are willing to spend for marginal benefit over what’s already out there.
The risk isn’t that mRNA vanishes. Its place in rapid response and as a tool for first-ever vaccines is secure. But can the current manufacturing scale and investment pay off, with only a handful of smaller, slower-moving indications? Juries out. Without another multi-billion-dollar government guarantee, mRNA vaccine economics look a lot more like routine biopharma: every indication a grind, blockbuster status still elusive. That’s reality in the post-pandemic cycle. Anyone promising another boom, at least for now, is selling something.
